ATE292677T1 - Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe - Google Patents

Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe

Info

Publication number
ATE292677T1
ATE292677T1 AT00964563T AT00964563T ATE292677T1 AT E292677 T1 ATE292677 T1 AT E292677T1 AT 00964563 T AT00964563 T AT 00964563T AT 00964563 T AT00964563 T AT 00964563T AT E292677 T1 ATE292677 T1 AT E292677T1
Authority
AT
Austria
Prior art keywords
methods
compositions
dna
agents
damageing
Prior art date
Application number
AT00964563T
Other languages
English (en)
Inventor
Masashi Suganuma
Takumi Kawabe
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP26939899A external-priority patent/JP2001086991A/ja
Priority claimed from JP34032299A external-priority patent/JP2001157585A/ja
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Application granted granted Critical
Publication of ATE292677T1 publication Critical patent/ATE292677T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT00964563T 1999-09-22 2000-09-21 Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe ATE292677T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP26939899A JP2001086991A (ja) 1999-09-22 1999-09-22 オリゴペプチド
JP34032299A JP2001157585A (ja) 1999-11-30 1999-11-30 抗癌療法の増強剤とそのスクリーニング方法
PCT/IB2000/001438 WO2001021771A2 (en) 1999-09-22 2000-09-21 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents

Publications (1)

Publication Number Publication Date
ATE292677T1 true ATE292677T1 (de) 2005-04-15

Family

ID=26548750

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964563T ATE292677T1 (de) 1999-09-22 2000-09-21 Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe

Country Status (11)

Country Link
US (2) US6881575B1 (de)
EP (1) EP1218494B1 (de)
JP (1) JP4610828B2 (de)
AT (1) ATE292677T1 (de)
AU (1) AU7548500A (de)
CA (1) CA2385257A1 (de)
DE (1) DE60019318T2 (de)
DK (1) DK1218494T3 (de)
ES (1) ES2239037T3 (de)
PT (1) PT1218494E (de)
WO (1) WO2001021771A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003052483A1 (fr) * 2001-12-17 2003-06-26 Olympus Corporation Systeme de microscope
JP4041066B2 (ja) * 2002-01-17 2008-01-30 武田薬品工業株式会社 抗増殖活性を有し、そして／または核酸損傷剤を増大するペプチドおよびペプチド模倣物あるいは処置
US7309597B2 (en) 2002-01-18 2007-12-18 Cargill, Incorporated Alanine 2,3-Aminomutase
JP4919598B2 (ja) 2002-06-06 2012-04-18 株式会社 キャンバス Ｄｎａ損傷誘発性細胞周期ｇ２チェックポイントを排除し、そして／またはｄｎａ損傷処置の抗癌活性を増強する化合物
DK1585749T3 (da) 2003-01-09 2008-09-22 Pfizer Diazepinoindol-derivater som kinaseinhibitorer
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
US7132440B2 (en) 2003-04-17 2006-11-07 Janssen Pharmaceutica, N.V. Substituted benzimidazoles and imidazo-[4,5]-pyridines
WO2004106924A2 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab Testing cell cycle regulation effect of a compound using a hollow fibre cell implant
JP4705567B2 (ja) * 2003-06-25 2011-06-22 株式会社 キャンバス 免疫調整活性、抗炎症活性、および抗ウイルス活性を有するペプチドおよびペプチド模倣物
EP1664340A1 (de) * 2003-08-08 2006-06-07 Canbas Co., Ltd. Empfindlichkeitstest zur vorhersage der wirksamkeit von antikrebstherapien
EP1660504B1 (de) 2003-08-29 2008-10-29 Pfizer Inc. Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
CA2539320A1 (en) * 2003-09-17 2005-03-31 Icos Corporation Use of chk1 inhibitors to control cell proliferation
CA2572218C (en) 2004-06-30 2013-06-11 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
US8084454B2 (en) 2007-04-11 2011-12-27 Canbas Co., Ltd. Compounds with anti-cancer activity
EP2409700A1 (de) 2007-05-08 2012-01-25 Schering Corporation Verfahren zur Behandlung mit intravenösen Formulierungen mit Temozolomid
CL2009001156A1 (es) * 2008-05-14 2010-08-27 Canbas Co Ltd Acetato de un peptido de 12 aminoacidos; metodo de preparacion; composicion farmaceutica y agente que lo contiene, solo o conjuntamente con un principio activo que dana el acido nucleico; util para el tratamiento o profilaxis de trastornos proliferativos celulares.
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
US20200206299A1 (en) * 2016-02-23 2020-07-02 Takeda Pharmaceutical Company Limited Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain
CN114470178A (zh) * 2019-12-05 2022-05-13 王连生 一种促进心肌再生的重组人chk1蛋白激酶水凝胶及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
AU6014998A (en) * 1997-01-13 1998-08-03 Pharmacia & Upjohn Company Special catalytic domains of cdc25c phosphatase

Also Published As

Publication number Publication date
AU7548500A (en) 2001-04-24
CA2385257A1 (en) 2001-03-29
DE60019318D1 (de) 2005-05-12
JP2003518368A (ja) 2003-06-10
US7851592B2 (en) 2010-12-14
DK1218494T3 (da) 2005-08-08
WO2001021771A2 (en) 2001-03-29
DE60019318T2 (de) 2006-03-09
JP4610828B2 (ja) 2011-01-12
WO2001021771A3 (en) 2002-02-14
EP1218494B1 (de) 2005-04-06
US6881575B1 (en) 2005-04-19
US20050059116A1 (en) 2005-03-17
EP1218494A2 (de) 2002-07-03
ES2239037T3 (es) 2005-09-16
PT1218494E (pt) 2005-08-31

Similar Documents

Publication Publication Date Title
ATE292677T1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
HRP20070189A2 (en) Use of erythropoietin
CY1111590T1 (el) Αρυλ και ετεροαρυλ ουριας αναστολεις chk1 για χρηση ως ραδιοευαισθοποιητες και χημειοευαισθητοποιητες
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
BRPI0409367A (pt) derivados de piperidina inibidores de renina
BRPI0616630B8 (pt) compostos de pirazol substituídos
TW200607513A (en) Certain chemical entities, compositions, and methods
TW200801008A (en) Protein kinase inhibitors
NO20061194L (no) Mitotiske kinesininbibitorer
AU2005253776A8 (en) Screening methods using c-Abl, Fyn and Syk in combination with tau protein
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE473728T1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
WO2001042784A3 (en) Methods for screening compounds active on neurons
WO2003076610A3 (fr) Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1218494

Country of ref document: EP